<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The selectivity of Lym-1 for malignant B lymphocytes makes this monoclonal antibody a promising candidate for the delivery of toxic agents to malignant B cells </plain></SENT>
<SENT sid="1" pm="."><plain>The original immunogen used for the development of Lym-1 was Raji Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell nuclei [Epstein A </plain></SENT>
<SENT sid="2" pm="."><plain>L., Marder R </plain></SENT>
<SENT sid="3" pm="."><plain>J., Winter J </plain></SENT>
<SENT sid="4" pm="."><plain>N., Stathopoulos E., Chen F </plain></SENT>
<SENT sid="5" pm="."><plain>M., Parker J </plain></SENT>
<SENT sid="6" pm="."><plain>W., Taylor C </plain></SENT>
<SENT sid="7" pm="."><plain>R </plain></SENT>
<SENT sid="8" pm="."><plain>(1987) <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Res 47: 830] </plain></SENT>
<SENT sid="9" pm="."><plain>The Lym-1 antigen was characterized at that time as a polymorphic HLA-DR variant </plain></SENT>
<SENT sid="10" pm="."><plain>We prepared an affinity column using immobilized Lym-1 to isolate the Lym-1 antigen from Raji cell lysate </plain></SENT>
<SENT sid="11" pm="."><plain>Immunological characterization of the immunoaffinity-purified Lym-1 antigen on Western blots led to the conclusion that the antigen is the beta chain of HLA-DR10 </plain></SENT>
<SENT sid="12" pm="."><plain>This was confirmed by Edman sequencing of the isolated <z:chebi fb="0" ids="16541">polypeptide chain</z:chebi> </plain></SENT>
<SENT sid="13" pm="."><plain>Western blots further show that the Lym-1 epitope is only recognized if the beta chain <z:chebi fb="0" ids="48343">disulfide</z:chebi> bonds are intact </plain></SENT>
<SENT sid="14" pm="."><plain>These results imply that Lym-1 binds a discontinuous <z:chebi fb="0" ids="53000">epitope</z:chebi> on the beta chain of HLA-DR10 </plain></SENT>
</text></document>